MARAbio
4 known investors
MARAbio develops a blood test for mothers that predicts the likelihood of Maternal Autoantibody Related Autism (MARA) in their child, detectable before pregnancy or as early as birth, and is also developing therapeutic interventions. The company targets early detection and mitigation of severe autism cases for care providers and expectant mothers.
Investors · 4
Also in the syndicate · 3
MAK CapitalleadMAK Capital OneleadMAK Capital One, LLClead
Funding
SEC filings, press & company announcements$19M disclosed across 1 of 2 rounds · 2024
- $19Mseries AOct 2024 · 5 sources
MAK Capital (lead), MAK Capital One (lead), MAK Capital One, LLC (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does MARAbio do?
- MARAbio develops a blood test for mothers that predicts the likelihood of Maternal Autoantibody Related Autism (MARA) in their child, detectable before pregnancy or as early as birth, and is also developing therapeutic interventions. The company targets early detection and mitigation of severe autism cases for care providers and expectant mothers.
- Who are MARAbio's investors?
- MARAbio's investors include AIF.
- How much funding has MARAbio raised?
- MARAbio has disclosed $19M raised across 1 of its 2 known rounds.